Arsenic does not enhance platelet activation, platelet/monocyte interaction or platelet/neutrophil aggregates formation.

<p>C57BL/6 wild-type and apoE^-/- mouse platelets were collected and exposed to arsenic (10, 50 or 200 ppb) and/or thrombin for 5 minutes. Representative pictures of platelet spreading after control, 200 ppb arsenic or 1U thrombin are shown in A (left panels: C57BL/6; right panels: apoE^-/-). (B) P-selectin (CD62) expression was assessed by flow cytometry (up panel: C57BL/6; down panel: apoE^-/-). (C) Circulating CCL5 levels were measured in apoE^-/- male mice were left untreated or exposed to 200 ppb arsenic for 8 or 13 weeks using an immunoassay kit (multiplex bead-based) on a Bio-Plex 200 (Bio-Rad Laboratories, ON, Canada). Each sample (n = 4) was analyzed in duplicate (technical replicate). (D-E) The platelet/monocyte aggregates (CD14⁺/CD41⁺; D) and the platelet/neutrophil aggregates (Ly6G⁺/CD41⁺; E) were followed from day 14 to 28 in the circulation of mice exposed to 200 ppb arsenic. One mouse, as positive control, was treated with LPS for 18 hours before the blood collection. Values are expressed as mean ± S.D., n ≥ 3 animals.